Products Summary:
The imugene product that treats blood cancers is Azer-cel. onCARlytics and the B cell pipeline are designed to treat solid tumours.CF33 is best thought of as potentially the first broad spectrum drug.
HER-Vaxx is narrow spectrum in that it can only be used to treat solid tumour that express the HER2 protein.
CF33 is the naked virus that targets only solid tumours. CF33 is infused in the Oncarlytics mix, hence this specific platform is heavily reliant on CF33/Vaxinia's effectiveness.
CF33 is already a component of Oncarlytics.
Although Oncarlytics may well have been designed to treat solid tumours, without the addition of CF33 it does not have the drug required to infect, explode and mop up the disintegrated cancer cells post contactVaxxinia is the strain with human sodium iodide symporter (hNIS) that targets only solid tumours.
Oncarlytics is the strain with hnis + cd19 shell that also only targets solid tumours.It is the blood cancer drugs that will be combined with the solid tumour drug, Oncarlytics.
That is where the crossover is. Oncarlytics is not the combination, just the solid tumour side of the combo. onCARlytics is CF33 with CD19 added.
Without CF33, the CD19 genes won’t be able to locate the tumours.
Information compiled (cut and paste ) from multiple HC contributors.
Products Summary:The imugene product that treats blood cancers...
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.2¢ |
Change
-0.001(1.89%) |
Mkt cap ! $382.1M | |||
| Open | High | Low | Value | Volume |
| 5.3¢ | 5.4¢ | 5.2¢ | $216.1K | 4.106M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 31 | 1854997 | 5.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.3¢ | 382882 | 4 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| IMU (ASX) Chart |